X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being developed for pneumonia.
Lead Product(s): Tosatoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
AR-301 (tosatoxumab), a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus, is being developed for pneumonia.
Lead Product(s): Tosatoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being developed for pneumonia.
Lead Product(s): Tosatoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
AR-301 (tosatoxumab) is a fully human IgG1 monoclonal antibody that specifically targets S. aureus alpha-toxin, an important virulence factor that is secreted by both methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus being developed for pneumonia.
Lead Product(s): Tosatoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2023
Details:
AstraZeneca terminated the collaboration with Aridis for the licensing of the AR-320 (suvratoxumab), a fully human, half-life extended IgG1 monoclonal antibody targeting S. aureus alpha toxin.
Lead Product(s): Suvratoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-320
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $126.0 million Upfront Cash: $11.0 million
Deal Type: Termination March 31, 2023
Details:
AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
AR-301 is a fully human IgG1 monoclonal antibody that targets S. aureus alpha-toxin (virulence factor that is secreted by both MRSA and MSSA). It is designed to protect against alpha-toxin mediated destruction of host cells, preserving a functional host immune response.
Lead Product(s): Tosatoxumab
Therapeutic Area: Infections and Infectious Diseases Product Name: AR-301
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
AR-501 is a novel inhaled formulation of gallium citrate with broad-spectrum anti-infective activity involving iron acquisition and metabolism, is being developed to treat chronic lung infections in cystic fibrosis (CF) patients.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
AR-501 is a novel, small molecule and an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: $12.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2022
Details:
The pan-Ebola program, MBP134, is a two mAb cocktail that has demonstrated effectiveness against Sudan virus (SUDV), Zaire Ebola virus (EBOV), Bundibugyo virus (BDBV), Taï Forest virus (TAFV), Reston virus (RESTV), and Bombali ebolavirus (BOMV).
Lead Product(s): MBP134
Therapeutic Area: Infections and Infectious Diseases Product Name: MBP134
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Mapp Biopharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 05, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
